ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 454

The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis

Jing Shi, H.W. van Steenbergen, J. a. B. van Nies, E.W.Nivine Levarht, Annette H. M. van der Helm- van Mil, Tom W. J. Huizinga, René E.M. Toes and Leendert A. Trouw, Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, diagnosis, Prognostic factors and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Anti-carbamylated protein (anti-CarP) antibodies have been described in rheumatoid arthritis (RA) and arthralgia patients [1;2] and occur in subsets of the anti-CCP2 positive and negative patients [1;3]. In anti-CCP2 negative RA patients the presence of anti-CarP was associated with more severe joint destruction [1]. Here we investigated the sensitivity and specificity of anti-CarP antibodies for RA in a setting of early arthritis.

Methods

Anti-carbamylated fetal calf serum (anti-Ca-FCS), anti-CCP2 antibodies and rheumatoid factor (RF) IgM were measured by ELISA using serum samples available from a large inception cohort; the Leiden Early Arthritis Clinic cohort (EAC). For the anti-CarP antibodies we used as a cut-off for positivity the mean + 2 times the standard deviation of the healthy controls [1].

Results

In total 2086 sera of Leiden EAC patients suffering from early arthritis were analyzed for the presence of anti-Ca-FCS antibodies. Anti-CarP antibodies were present in 26% of the patients and in 2% of the controls. We observed that the sensitivity and specificity of anti-Ca-FCS in the EAC cohort for RA are 44% and 89%. As a reference the sensitivity and specificity of anti-CCP2 antibodies are 54% and 95% and for RF IgM are 59% and 90%. Analyzing the early arthritis patients that did not fulfil the EULAR/ACR 2010 criteria for RA that were anti-CarP positive (n=127) revealed that these patients were mainly diagnosed as undifferentiated arthritis (45%), reactive arthritis (9%), psoriatic arthritis (9%) or peripheral spondyloarthritis (8%).

Conclusion

Anti-CarP antibodies, as determined by the reactivity to carbamylated FCS, are predominantly present in RA but can also be detected in other forms of arthritis. The prognostic relevance of anti-CarP antibodies in these latter patients will have to be determined.

1.    Shi J et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc.Natl.Acad.Sci.U.S.A 2011; 108:17372-7.

2.    Shi J, van de Stadt LA, et al. Anti Carbamylated Protein Antibodies (anti-CarP) are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2012.

3.    Jiang X, Trouw LA, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann.Rheum.Dis. 2014.


Disclosure:

J. Shi,
None;

H. W. van Steenbergen,
None;

J. A. B. van Nies,
None;

E. W. N. Levarht,
None;

A. H. M. van der Helm- van Mil,
None;

T. W. J. Huizinga,
None;

R. E. M. Toes,
None;

L. A. Trouw,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-specificity-of-anti-carbamylated-protein-antibodies-for-rheumatoid-arthritis-in-a-setting-of-early-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology